| Identification | Back Directory | [Name]
Evenamide | [CAS]
1092977-61-1 | [Synonyms]
NW-3509
Evenamide
2-((3-butoxyphenethyl)amino)-N,N-dimethylacetamide
N2-[2-(3-Butoxyphenyl)ethyl]-N,N-dimethylglycinamide
Acetamide, 2-[[2-(3-butoxyphenyl)ethyl]amino]-N,N-dimethyl-
psychosis,mania,voltage,Inhibitor,inhibit,gated,Na+ channels,Na channels,aggressiveness,schizophrenia,NW3509,channel,sodium,Sodium Channel,VGSC,depression,NW 3509,Evenamide | [Molecular Formula]
C16H26N2O2 | [MOL File]
1092977-61-1.mol | [Molecular Weight]
278.39 |
| Chemical Properties | Back Directory | [Boiling point ]
412.1±30.0 °C(Predicted) | [density ]
1.012±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: 290 mg/mL (1041.70 mM) | [form ]
Liquid | [pka]
7.99±0.19(Predicted) | [color ]
Colorless to light yellow |
| Hazard Information | Back Directory | [Uses]
Evenamide (NW-3509) is an orally available voltage-gated sodium channel (VGSC) blocker (Ki=0.4 μM) for the research of schizophrenia. Evenamide shows efficacy in a broad spectrum of rodent models of psychosis, mania, depression, and aggressiveness[1][2]. | [in vivo]
Evenamide is active in a wide range of psychiatric animal models in monotherapy and addon to antipsychotics. Evenamide is effective in attenuating the social interaction deficit in Cl 395 (PCP)-impaired rats (MED=1 mg/kg po)[2]. | [storage]
Store at -20°C | [References]
[1] Valentina Zuliani, et al. Advances in Design and Development of Sodium Channel Blockers. Ion Channels and Their Inhibitors pp 79-115.
[2] Faravelli, et al. P.3.f.022 Evenamide (formerly NW-3509) targets new mechanisms, and represents a new approach to the management of untreated symptoms in schizophrenia. |
|
| Company Name: |
parabiochem
|
| Tel: |
025-83453382-8005 |
| Website: |
www.parabiochem.cn |
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 13348960310; |
| Website: |
https://www.weikeqi-biotech.com/ |
|